FMP
NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
26.03 USD
0.08 (0.307%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Michael Harvey Davidson FACC, Facp., M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
CIK
0001936258
ISIN
NL00150012L7
CUSIP
N/A
Address
Gooimeer 2-35
Phone
31 35 206 2971
Country
NL
Employee
62
IPO Date
Feb 9, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
NAMS Financial Summary
CIK
0001936258
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
NL00150012L7
Country
NL
Price
26.03
Beta
-0
Volume Avg.
745.73k
Market Cap
2.78B
Shares
-
52-Week
10.502-27.29
DCF
4.57
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.78
P/B
-
Website
https://www.newamsterdampharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NAMS News
It looks like there's no news available.
